BreezeBio secures $60 million in Series B financing to enhance its pipeline of precision genetic medicines and expand its NanoGalaxy delivery platform.
Amount Raised
$60 Million
Round Type
Series B
South San FranciscoBiotechnologyHealth CareTherapeuticsInvestors
Description
BreezeBio, formerly known as GenEdit, has completed its Series B financing round, raising $60 million. This funding will support the advancement of BreezeBio's therapeutic programs toward clinic readiness and extend the capabilities of its NanoGalaxy delivery platform. CEO Kunwoo (Ryan) Lee emphasized the significance of this financing in progressing their therapeutic development. The lead candidate, BRZ-101, targets type 1 diabetes through a novel immune modulation approach.
Quick answer
BreezeBio raised $60 Million in a Series B round, dated February 25, 2026. Investors: KDB Silicon Valley, Woori Venture Partners, Dayli Partners, Top Harvest Capital and STIC Ventures. BreezeBio is based in South San Francisco, California, United States.
- How much did BreezeBio raise?
- BreezeBio raised $60 Million in a Series B round on February 25, 2026.
- Who invested in BreezeBio?
- KDB Silicon Valley, Woori Venture Partners, Dayli Partners, Top Harvest Capital and STIC Ventures are named as investors in this round.
- What does BreezeBio do?
- BreezeBio, formerly known as GenEdit, is focused on developing precision genetic medicines using its proprietary NanoGalaxy delivery platform.
- Where is BreezeBio based and how big is it?
- BreezeBio is based in South San Francisco, California, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as BreezeBio that raised within 45 days of this round, from Fundz verified event records.
- Sidewinder Therapeutics raised $137M (Series B) on April 8, 2026.
- Marvel Biosciences raised an undisclosed amount (Funding Round) on April 7, 2026.
- TransCode Therapeutics raised $20M (Funding Round) on April 7, 2026.
- TippingPoint Biosciences raised $4.5M (Seed) on March 31, 2026.
- Denali Therapeutics raised $200M (Debt Financing) on March 31, 2026.
- Sonire Therapeutics raised $18M (Series A) on March 31, 2026.
Who to call at BreezeBio, and when
A new round usually means BreezeBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day BreezeBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BreezeBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BreezeBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BreezeBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansBreezeBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.